Synapse

← Paul M. Ridker

Papers by Paul M. Ridker

Page 7 · newest first

  1. Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated PatientsCirculation · 2013
  2. A Prospective Study of Circulating C-Reactive Protein, Interleukin-6, and Tumor Necrosis Factor α Receptor 2 Levels and Risk of Ovarian CancerAmerican Journal of Epidemiology · 2013
  3. High-Dose Statin Therapy in Patients With Stable Coronary Artery DiseaseCirculation · 2013
  4. A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) ConsortiumGenetic Epidemiology · 2013
  5. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk scoreHeart · 2013
  6. Effect of dietary composition of weight loss diets on high‐sensitivity c‐reactive protein: The Randomized POUNDS LOST trialObesity · 2013
  7. Novel genetic markers improve measures of atrial fibrillation risk predictionEuropean Heart Journal · 2013
  8. Sugar-Sweetened Beverages and Genetic Risk of ObesityObstetrical & Gynecological Survey · 2013
  9. C-Reactive Protein and the Incidence of Macular Degeneration: Pooled Analysis of 5 CohortsJAMA Ophthalmology · 2013
  10. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical careEuropean Heart Journal · 2013
  11. Novel locus including FGF21 is associated with dietary macronutrient intakeHuman Molecular Genetics · 2013
  12. Prospective Evaluation of B-type Natriuretic Peptide Concentrations and the Risk of Type 2 Diabetes in WomenClinical Chemistry · 2013
  13. Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and FibrinogenCirculation · 2012
  14. Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A ₂ Mass and Activity at Baseline and After Rosuvastatin TherapyCirculation Cardiovascular Genetics · 2012
  15. Sugar-Sweetened Beverages and Genetic Risk of ObesityNew England Journal of Medicine · 2012
  16. Lipid-Modifying Therapies and Risk of PancreatitisENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2012
  17. Plasma Adiponectin and the Risk of Hypertension in White and Black Postmenopausal WomenClinical Chemistry · 2012
  18. Clinical Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Disease Prediction in a Multiethnic Cohort of WomenClinical Chemistry · 2012
  19. An X Chromosome Association Scan of the Norfolk Island Genetic Isolate Provides Evidence for a Novel Migraine Susceptibility Locus at Xq12PLoS ONE · 2012
  20. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsJAMA · 2012
  21. Reproductive aging-associated common genetic variants and the risk of breast cancerBreast Cancer Research · 2012
  22. Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequalityBMC Public Health · 2012
  23. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trialCanadian Medical Association Journal · 2012
  24. Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER TrialClinical Chemistry · 2012
  25. Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health InitiativeCirculation · 2012
  26. Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular PreventionJournal of the American Heart Association · 2012
  27. Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol ReductionCirculation Cardiovascular Genetics · 2012
  28. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyThrombosis and Haemostasis · 2011
  29. Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Data from the Women's Health StudyPLoS ONE · 2011
  30. Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 LevelsAnnals of Internal Medicine · 2011
  31. Association of HDL Cholesterol with Incident Cardiovascular Events by LDL Cholesterol and Apolipoprotein B100 in WomenAnnals of Internal Medicine · 2011
  32. Physical Activity and Inflammation in a Multiethnic Cohort of WomenMedicine & Science in Sports & Exercise · 2011
  33. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effectsEuropean Heart Journal · 2011
  34. Geographic Variation in Cardiovascular Inflammation among Healthy Women in the Women's Health StudyPLoS ONE · 2011
  35. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER TrialClinical Chemistry · 2011
  36. High-Molecular-Weight and Total Adiponectin Levels and Incident Symptomatic Peripheral Artery Disease in WomenCirculation · 2011
  37. Association of Variation at the ABO Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectinCirculation Cardiovascular Genetics · 2011
  38. A tale of three labels: translating the JUPITER trial data into regulatory claimsClinical Trials · 2011
  39. C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib TreatmentCancer Prevention Research · 2011
  40. Genetic Determinants of Cardiovascular Events among Women with Migraine: A Genome-Wide Association StudyPLoS ONE · 2011
  41. The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in womenVascular Medicine · 2011
  42. Smoking, Smoking Cessation, and Risk for Symptomatic Peripheral Artery Disease in WomenAnnals of Internal Medicine · 2011
  43. Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes MellitusCirculation · 2011
  44. Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 LociPLoS Genetics · 2011
  45. Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary PreventionCirculation Cardiovascular Genetics · 2011
  46. Circulating Inflammatory and Endothelial Markers and Risk of Hypertension in White and Black Postmenopausal WomenClinical Chemistry · 2011
  47. Physical Activity Modifies the Effect of LPL, LIPC , and CETP Polymorphisms on HDL-C Levels and the Risk of Myocardial Infarction in Women of European AncestryCirculation Cardiovascular Genetics · 2011
  48. Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health StudyJournal of Hypertension · 2010
  49. Variation in RecoveryCirculation Cardiovascular Quality and Outcomes · 2010
  50. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authoritiesEuropean Heart Journal · 2010